Bergenbio ASA Asset Resilience Ratio
Bergenbio ASA asset resilience ratio. Bergenbio ASA (BGBIO) has an Asset Resilience Ratio of 89.96% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BGBIO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bergenbio ASA (2016–2024)
Asset resilience ratio of Bergenbio ASA from 2016 to 2024. This chart shows how Bergenbio ASA's Asset Resilience Ratio has changed over time. Read Bergenbio ASA balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bergenbio ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Bergenbio ASA.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr140.16 Million | 89.96% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr140.16 Million | 89.96% |
Asset Resilience Insights
- Very High Liquidity: Bergenbio ASA maintains exceptional liquid asset reserves at 89.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Bergenbio ASA Industry Peers by Asset Resilience Ratio
Compare Bergenbio ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Bergenbio ASA Asset Resilience Ratio by Year (2016–2024)
Bergenbio ASA asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Bergenbio ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 89.96% | Nkr140.16 Million ≈ $14.75 Million |
Nkr155.80 Million ≈ $16.39 Million |
+0.24pp |
| 2023-12-31 | 89.72% | Nkr156.42 Million ≈ $16.46 Million |
Nkr174.34 Million ≈ $18.35 Million |
-0.74pp |
| 2022-12-31 | 90.46% | Nkr150.80 Million ≈ $15.87 Million |
Nkr166.71 Million ≈ $17.54 Million |
-6.52pp |
| 2021-12-31 | 96.98% | Nkr436.65 Million ≈ $45.95 Million |
Nkr450.24 Million ≈ $47.38 Million |
-0.78pp |
| 2020-12-31 | 97.76% | Nkr721.64 Million ≈ $75.94 Million |
Nkr738.20 Million ≈ $77.68 Million |
+3.97pp |
| 2019-12-31 | 93.79% | Nkr253.59 Million ≈ $26.68 Million |
Nkr270.38 Million ≈ $28.45 Million |
-1.35pp |
| 2018-12-31 | 95.14% | Nkr360.41 Million ≈ $37.93 Million |
Nkr378.83 Million ≈ $39.86 Million |
-1.22pp |
| 2017-12-31 | 96.36% | Nkr370.35 Million ≈ $38.97 Million |
Nkr384.34 Million ≈ $40.44 Million |
+3.64pp |
| 2016-12-31 | 92.72% | Nkr161.82 Million ≈ $17.03 Million |
Nkr174.54 Million ≈ $18.37 Million |
-- |
About Bergenbio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.